Aroa Biosurgery Ltd (ARX) - Total Assets
Based on the latest financial reports, Aroa Biosurgery Ltd (ARX) holds total assets worth AU$95.27 Million AUD (≈ $67.41 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See what is Aroa Biosurgery Ltd's book value for net asset value and shareholders' equity analysis.
Aroa Biosurgery Ltd - Total Assets Trend (2001–2025)
This chart illustrates how Aroa Biosurgery Ltd's total assets have evolved over time, based on quarterly financial data.
Aroa Biosurgery Ltd - Asset Composition Analysis
Current Asset Composition (March 2025)
Aroa Biosurgery Ltd's total assets of AU$95.27 Million consist of 62.6% current assets and 37.4% non-current assets.
| Asset Category | Amount (AUD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$0.00 | 7.3% |
| Accounts Receivable | AU$14.84 Million | 15.0% |
| Inventory | AU$7.52 Million | 7.6% |
| Property, Plant & Equipment | AU$21.51 Million | 21.7% |
| Intangible Assets | AU$12.33 Million | 12.5% |
| Goodwill | AU$5.03 Million | 5.1% |
Asset Composition Trend (2001–2025)
This chart illustrates how Aroa Biosurgery Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see how much is Aroa Biosurgery Ltd worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Aroa Biosurgery Ltd's current assets represent 62.6% of total assets in 2025, an increase from 0.0% in 2001.
- Cash Position: Cash and equivalents constituted 7.3% of total assets in 2025, down from 72.2% in 2001.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 17.0% of total assets, an increase from 0.0% in 2001.
- Asset Diversification: The largest asset category is property, plant & equipment at 21.7% of total assets.
Aroa Biosurgery Ltd Competitors by Total Assets
Key competitors of Aroa Biosurgery Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Vitrolife AB
ST:VITR
|
Sweden | Skr11.12 Billion |
|
Medprin Regenerative Medical Technologies Co. Ltd.
SHE:301033
|
China | CN¥805.10 Million |
|
Tellgen Corp
SHE:300642
|
China | CN¥2.00 Billion |
|
Lumos Diagnostics Holdings Ltd
AU:LDX
|
Australia | AU$20.81 Million |
|
T&R Biofab Co. Ltd
KQ:246710
|
Korea | ₩83.86 Billion |
|
Ok Biotech Co Ltd
TW:4155
|
Taiwan | NT$3.89 Billion |
|
Promimic AB
ST:PRO
|
Sweden | Skr75.71 Million |
|
Memphasys Ltd
AU:MEM
|
Australia | AU$10.45 Million |
Aroa Biosurgery Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 6.52 | 8.53 | 12.48 |
| Quick Ratio | 5.74 | 7.31 | 11.48 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | AU$50.46 Million | AU$51.90 Million | AU$43.17 Million |
Aroa Biosurgery Ltd - Advanced Valuation Insights
This section examines the relationship between Aroa Biosurgery Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.57 |
| Latest Market Cap to Assets Ratio | 1.53 |
| Asset Growth Rate (YoY) | -2.9% |
| Total Assets | AU$98.94 Million |
| Market Capitalization | $150.91 Million USD |
Valuation Analysis
Above Book Valuation: The market values Aroa Biosurgery Ltd's assets above their book value (1.53x), reflecting positive investor sentiment about the company's future prospects.
Slight Asset Contraction: Aroa Biosurgery Ltd's assets decreased by 2.9% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Aroa Biosurgery Ltd (2001–2025)
The table below shows the annual total assets of Aroa Biosurgery Ltd from 2001 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-03-31 | AU$98.94 Million ≈ $70.01 Million |
-2.89% |
| 2024-03-31 | AU$101.88 Million ≈ $72.09 Million |
-6.60% |
| 2023-03-31 | AU$109.07 Million ≈ $77.17 Million |
+4.17% |
| 2022-03-31 | AU$104.71 Million ≈ $74.09 Million |
+43.19% |
| 2021-03-31 | AU$73.12 Million ≈ $51.74 Million |
-11.40% |
| 2020-03-31 | AU$82.54 Million ≈ $58.40 Million |
+117.42% |
| 2019-03-31 | AU$37.96 Million ≈ $26.86 Million |
+165.41% |
| 2018-03-31 | AU$14.30 Million ≈ $10.12 Million |
+119.53% |
| 2017-03-31 | AU$6.52 Million ≈ $4.61 Million |
+2.51% |
| 2016-03-31 | AU$6.36 Million ≈ $4.50 Million |
-15.37% |
| 2015-03-31 | AU$7.51 Million ≈ $5.31 Million |
-10.66% |
| 2014-03-31 | AU$8.41 Million ≈ $5.95 Million |
-10.16% |
| 2013-03-31 | AU$9.36 Million ≈ $6.62 Million |
-14.38% |
| 2012-03-31 | AU$10.93 Million ≈ $7.73 Million |
+35.33% |
| 2011-03-31 | AU$8.07 Million ≈ $5.71 Million |
+57.38% |
| 2010-03-31 | AU$5.13 Million ≈ $3.63 Million |
-93.82% |
| 2009-03-31 | AU$83.08 Million ≈ $58.79 Million |
+16.03% |
| 2008-03-31 | AU$71.60 Million ≈ $50.66 Million |
-19.12% |
| 2007-03-31 | AU$88.53 Million ≈ $62.64 Million |
+118.18% |
| 2006-03-31 | AU$40.58 Million ≈ $28.71 Million |
+107.03% |
| 2005-03-31 | AU$19.60 Million ≈ $13.87 Million |
+26.93% |
| 2004-03-31 | AU$15.44 Million ≈ $10.93 Million |
+27.39% |
| 2003-03-31 | AU$12.12 Million ≈ $8.58 Million |
-1.97% |
| 2002-03-31 | AU$12.37 Million ≈ $8.75 Million |
-10.73% |
| 2001-03-31 | AU$13.85 Million ≈ $9.80 Million |
-- |
About Aroa Biosurgery Ltd
Aroa Biosurgery Limited develops, manufactures, and sells medical devices for wound and soft tissue repair using extracellular matrix (ECM) technology in the United States and internationally. Its products include Endoform Natural and Endoform Antimicrobial Restorative Bioscaffold for treating acute and chronic wounds; Myriad Matrix, an engineered ECM for soft tissue repair, reinforcement, and co… Read more